IndraLab
Statements
reach
"In this study, we showed that USP2 is a new bona fide deubiquitylase of SKP2, which is supported by the following lines of evidence: (1) SKP2 binding with USP2 under physiological conditions; (2) the levels of endogenous SKP2 are directly regulated by USP2 manipulation with USP2 knockdown to decrease and USP2 overexpression to increase SKP2; (3) USP2 stabilized SKP2 by cleaving SKP2 polyubiquitylation chains to extend SKP2 half-life; (4) pharmacologic inhibition of USP2 significantly impaired SKP2 stability; and (5) USP2 catalytic-inactive mutant USP2–C276A had no effect on SKP2."
reach
"Our study fits the following working model that USP2 has a dual role in stabilizing both SKP2 and SKP2 substrate through binding to the LRR domain on SKP2: (a) when SKP2 is free of USP2 binding, it promotes the degradation of p21 and p27, and (b) when SKP2 binds to USP2, p21 and p27 are freed up and stabilized (Fig. 6E)."
sparser
"In this study, we showed that USP2 is a new bona fide deubiquitylase of SKP2, which is supported by the following lines of evidence: (1) SKP2 binding with USP2 under physiological conditions; (2) the levels of endogenous SKP2 are directly regulated by USP2 manipulation with USP2 knockdown to decrease and USP2 overexpression to increase SKP2; (3) USP2 stabilized SKP2 by cleaving SKP2 polyubiquitylation chains to extend SKP2 half-life; (4) pharmacologic inhibition of USP2 significantly impaired SKP2 stability; and (5) USP2 catalytic-inactive mutant USP2–C276A had no effect on SKP2."
sparser
"We further confirmed that ectopic expression of WT USP2, but not of its catalytic-inactive mutant USP2–C276A, caused accumulation of endogenous SKP2 in a dose-dependent manner ( xref D ), and endogenous USP2 and SKP2 bound to each other under a physiological condition detected in a reciprocal immunoprecipitation (IP) assay ( xref E )."